GERN - ジェロン （Geron Corporation） ジェロンGERNのチャート
GERNの企業情報
| symbol | GERN |
|---|---|
| 会社名 | Geron Corp. （ジェロン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ジェロン（Geron Corporation）はJanssen Biotech Inc. (Janssen)による血液骨髄性悪性腫瘍でファーストインクラスのテロメラーゼ阻害剤、imetelstatを開発する臨床段階のバイオ医薬品会社である。同社は、腫瘍学治療薬の開発に従事している。テロメラーゼのリボ核酸（RNA）鋳型に高親和性で結合し、それによってテロメラーゼ活性を直接阻害するオリゴヌクレオチドであるように、その核酸化学を用いて、イメテスタットを設計した。JanssenはIMbarkと呼ばれる骨髄線維症（MF）の第II相試験、IMergeと呼ばれる骨髄異形成症候群（MDS）の第II / III相試験などの2つの臨床試験でImetelstatの開発に従事する。Imetelstatは、テロメラーゼのRNA鋳型に相補的であり、それと高親和性で結合するように設計され、それによってテロメラーゼ活性を直接阻害するように設計された脂質結合13merオリゴヌクレオチドである。 ジェロンは米国のバイオ医薬品会社で、抗がん剤の開発に焦点に置く。現在製品化に向け、リンパ増殖性疾患、多発性骨髄腫、非小細胞肺がん、乳がん、急性骨髄性白血病のテロメラ―ゼ阻害剤であるイメテルスタットの治験を行う。また、骨髄線維症に対するテロメラ―ゼ阻害剤の予備研究を行う。 Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. |
| 本社所在地 | 149 Commonwealth Drive Suite 2070 Menlo Park CA 94025 USA |
| 代表者氏名 | Hoyoung Huh 湖寧 |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-473-7700 |
| 設立年月日 | 33178 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1996年 |
| 従業員数 | 42人 |
| url | www.geron.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gern |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -29.64000 |
| 終値（lastsale） | 1.835 |
| 時価総額（marketcap） | 336946417.71 |
| 時価総額 | 時価総額（百万ドル） 306.64880 |
| 売上高 | 売上高（百万ドル） 0.88000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 145.72180 |
| 当期純利益 | 当期純利益（百万ドル） -28.44800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Geron Corporation revenues decreased 26% to $526K. Net loss increased 4% to $14.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 23% to $6.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.09 to -$0.08. |
GERNのテクニカル分析
GERNのニュース
Geron: Ready To Face The Competition With Imetelstat In Lower Risk Myelodysplastic Syndromes 2023/05/31 13:47:21 Seeking Alpha
Geron is executing in the clinic with success in IMerge, and other studies are set to read out in late 2023, 2024, and beyond. Find out why GERN stock is a Buy.
Geron on track for imetelstat myelodysplastic syndromes NDA submission in June 2023/05/25 21:56:34 Seeking Alpha
Geron (GERN) said that its planned New Drug Application for imetelstat for lower risk myelodysplastic syndromes is on track for submission in June. Read more here.
Geron (GERN) Q1 2023 Earnings Call Transcript 2023/05/11 22:30:54 The Motley Fool
GERN earnings call for the period ending March 31, 2023.
Geron Corporation (GERN) Q1 2023 Earnings Call Transcript 2023/05/11 17:38:05 Seeking Alpha
Geron Corporation (NASDAQ:NASDAQ:GERN) Q1 2023 Results Conference Call May 11, 2023 10:30 AM ETCompany ParticipantsAron Feingold - VP, IR and Corporate CommunicationsDr.
Geron Corporation: Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 2023/05/11 14:06:00 Finanz Nachrichten
Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong correla…
Geron Corporation Shares Rise 70.62% From The Lows – But Will They Continue? 2023/01/27 14:00:00 Marketing Sentinel
In last trading session, Geron Corporation (NASDAQ:GERN) saw 3.3 million shares changing hands with its beta currently measuring 0.69. Company’s recent per share price level of $3.37 trading at -$0.03 or -0.88% at ring of the bell on the day assigns it a market valuation of $1.24B. That closing price of GERN’s stock is at … Geron Corporation Shares Rise 70.62% From The Lows – But Will They Continue? Read More »
7 A-Rated Stocks to Buy for Less Than $25 2023/01/24 11:15:09 InvestorPlace
The overall stock market may be demonstrating resilience, but as uncertainty continues to run high, stocks have only made a modest, partial recovery. However, this works to your advantage, as many stocks remain at low prices, including the best stocks to buy for less than $25 per share. Although investors are starting to wager on a 2023 pivot on interest rates by the Federal Reserve , inflation remains at multi-decade highs. The Fed could still decide to keep raising rates until inflation starts to ease. With this, there may be a round or two of additional volatility before the bull market returns. Yet if you focus on high-quality lower-priced stocks, this isn’t a major concern. These names can handle additional volatility. Some of these could perform strongly with secular growth catalysts even if the overall stock market stays in a slump throughout the year. So, what are the best stocks to buy for less than $25 per share? Consider these seven. Each one earns an A rating in Portfolio Grader.
Charming stocks: Geron Corporation (NASDAQ:GERN 3.91%), Walmart Inc. (NYSE:WMT 1.23%) 2023/01/23 01:27:05 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Charming stocks: Geron Corporation (NASDAQ:GERN 3.91%), Walmart Inc. (NYSE:WMT 1.23%) appeared first on Stocks Equity .
Geron lines up commercial leadership for imetelstat launch 2023/01/11 18:47:47 Seeking Alpha
Geron Corporation (GERN) announced new additions to its senior commercial leadership on Wednesday ahead of the planned launch of blood cancer therapy imetelstat. Read the full story here.
Geron''s Data Allows Development Of Several Catalysts (GERN) 2023/01/10 00:01:36 Seeking Alpha
Primary endpoint of 8-week transfusion independence met in Geron Corporation''s phase 3 IMerge study. Read more to see why I''m bullish on GERN.
Geron (GERN) Stock: Expect Topline MDS Data In Early January 2022/12/02 01:50:55 Seeking Alpha
Geron will topline its IMerge trial by early January, a pivotal event in the life of the company. Read more to see my recommendation on GERN stock.
Geron Corporation (GERN) Outlook: Revisiting The Past For Future Insights 2022/11/25 12:00:00 Stocks Register
Geron Corporation (NASDAQ:GERN) concluded the trading at $2.20 on Wednesday, November 23 with a fall of -2.65% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.26 and 5Y monthly beta was reading 0.76 with its price kept floating in the range … Geron Corporation (GERN) Outlook: Revisiting The Past For Future Insights Read More »
Geron Corporation (GERN) Suffers From Weak Fundamental Momentum 2022/11/22 14:00:00 Marketing Sentinel
Geron Corporation (NASDAQ:GERN) has a beta value of 0.78 and has seen 2.95 million shares traded in the last trading session. The company, currently valued at $816.05M, closed the last trade at $2.15 per share which meant it lost -$0.11 on the day or -4.87% during that session. The GERN stock price is -42.33% off … Geron Corporation (GERN) Suffers From Weak Fundamental Momentum Read More »
Observations on the Geron Corporation (NASDAQ:GERN) Growth Curve 2022/11/08 18:00:00 US Post News
Geron Corporation (GERN)’s stock has witnessed a price hike of 5.82% from the previous close with its current price standing at $2.22. Its current price is -27.38% under its 52-week high of $3.06 and 124.49% more than its 52-week low of $0.99. Based on the past 30-day period, the stock price is -10.51% below the […]
Geron to Participate in Stifel 2022 Healthcare Conference 2022/11/07 21:30:00 Business Wire
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET. A webcast of the presentation will be ava